An important component to our program is facilitating “real world” experiences for our interested students in the areas of drug development, genomics, pharmacology/toxicology and drug policy. During the summer of 2007, several of our students participated in internships at the FDA as part of the Critical Path (C-Path) Initiative Program (http://www.c-path.org/) and GWUMC. Listed below are the details of each of their projects. We would like to congratulate all of these students on a job well done!

Summer 2007

FDA/Critical Path Initiative Internships

• Ngoc-Han Ha:  Two projects

Dr. Maryellen de Mars (Critical Path Initiative) Pharmacogenomic Tests in Warfarin Studies

Dr. Joga Gobboru (FDA) Best Practice for Assessing Effect of Age on Pediatric PK

• Osman Kargbo:

Dr. William Mattes (C-Path) PSTC Study and Sample Inventory Database

• Lamia Hachani

Dr. Federico Goodsaid (FDA) Genetic Markers of Clinical Outcome in Tuberculosis

• Shiva Salartash

Dr. Karol Thompson (FDA) Comparison of in vitro and in vivo effects of rosiglitazone on cardiac myocytes

GWUMC Internships

• Ngoc-Han Ha

Drs. Travis O’Brien (GWUMC), Arthur Harralson (SU) Impact of polymorphisms in CYP2C9 on warfarin dosing requirements

• Preston Witcher

Dr. Travis O’Brien (GWUMC) Role of translesion DNA synthesis in hexavalent chromium-induced mutagenesis